Abstract:Objective: To evaluate the diagnostic accuracy of the Fetal Medicine Foundation (FMF) competing-risks model, incorporating maternal characteristics, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI) and placental growth factor (PlGF) (the 'triple test'), for the prediction at 11-13 weeks' gestation of preterm pre-eclampsia (PE) in a Spanish population. Methods: This was a prospective cohort study performed in eight fetal medicine units in five different regions of Spain between September 2017 and December 2019. All pregnant women with a singleton pregnancy and a non-malformed live fetus attending a routine ultrasound examination at 11 + 0 to 13 + 6 weeks' gestation were invited to participate. Maternal demographic characteristics and medical history were recorded and MAP, UtA-PI, serum PlGF and pregnancy-associated plasma protein-A (PAPP-A) were measured following standardized protocols. Treatment with aspirin during pregnancy was also recorded. Raw values of biomarkers were converted into multiples of the median (MoM), and audits were performed periodically to provide regular feedback to operators and laboratories. Patient-specific risks for term and preterm PE were calculated according to the FMF competing-risks model, blinded to pregnancy outcome. The performance of screening for PE, taking into account aspirin use, was assessed by calculating the area under the receiver-operating-characteristics curve (AUC) and detection rate (DR) at a 10% fixed screen-positive rate (SPR). Risk calibration of the model was assessed. Results: The study population comprised 10 110 singleton pregnancies, including 72 (0.7%) that developed preterm PE. In the preterm PE group, compared to those without PE, median MAP MoM and UtA-PI MoM were significantly higher, and median serum PlGF MoM and PAPP-A MoM were significantly lower. In women with PE, the deviation from normal in all biomarkers was inversely related to gestational age at delivery. Screening for preterm PE by a combination of maternal characteristics and medical history with MAP, UtA-PI and PlGF had a DR, at 10% SPR, of 72.7% (95% CI, 62.9-82.6%). An alternative strategy of replacing PlGF with PAPP-A in the triple test was associated with poorer screening performance for preterm PE, giving a DR of 66.5% (95% CI, 55.8-77.2%). The calibration plot showed good agreement between predicted risk and observed incidence of preterm PE, with a slope of 0.983 (95% CI, 0.846-1.120) and an intercept of 0.154 (95% CI, -0.091 to 0.397). Conclusions: The FMF model is effective in predicting preterm PE in the Spanish population at 11-13 weeks' gestation. This method of screening is feasible to implement in routine clinical practice, but it should be accompanied by a robust audit and monitoring system, in order to maintain high-quality screening. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.

OP13.04: Predictive performance of combined screening plus PlGF for fetal growth restriction

Fetal Growth Restriction: Does an Integrated Maternal Hemodynamic-Placental Model Fit Better?

EP17.09: Performance of sFlt1 ‐PlGF ratio at 35–36 weeks of gestation in nulliparous women in identifying SGA, pre‐eclampsia and FGR

EP08.51: Machine learning methods to predict fetal growth restriction: a systematic review

OP15.05: First trimester fetal growth: a screening tool for small‐for‐gestational‐age newborns

OP05.01: Impact of Doppler and gestational age on the prediction of adverse perinatal outcome in fetuses with late‐onset fetal growth restriction

OP05.05: Longitudinal Doppler assessment and perinatal outcomes in early‐set intrauterine growth restriction fetuses

The role of the PLGF in the prediction of the outcome in pregnancies with a small for gestational age fetus

Performance of first-trimester combined screening for preterm pre-eclampsia: findings from cohort of 10 110 pregnancies in Spain

Prediction of Late-Onset Small for Gestational Age and Fetal Growth Restriction by Fetal Biometry at 35 Weeks and Impact of Ultrasound–Delivery Interval: Comparison of Six Fetal Growth Standards

Risk evaluation of fetal growth restriction by combined screening in early and mid-pregnancy

OP01.09: Ultrasound predictors of abnormal severe neonatal outcomes in late fetal growth restriction

Clinical utility of sFlt‐1 and PlGF in screening, prediction, diagnosis and monitoring of pre‐eclampsia and fetal growth restriction

EP08.10: Sonographic surveillance and perinatal outcomes among pregnancies with periviable fetal growth restriction

OC02.03: *Correlation of angiogenic factors PlGF and sFlt‐1 with severity stages of fetal growth restriction

762: Risk for preeclampsia and intrauterine growth restriction: effective value of PlGF, Sflt-1 and Inhibin A in singleton and multiple pregnancies

Maternal serum placental growth factor combined with second trimester aneuploidy screening to predict small-for-gestation neonates without preeclampsia

EP08.43: Sonographic surveillance and neonatal outcomes among pregnancies with periviable fetal growth restriction

OP13.08: Efficiency of cerebroplacental ratio in identifying high‐risk late‐ and post‐term pregnancies

OC02.06: Assessment of placental perfusion and volume with MR IVIM model and correlation with fetoplacental Doppler in late‐onset fetal growth restriction

OP01.08: Value of adding angiogenic factors to ultrasound Doppler criteria in the definition of fetal growth restriction